Actionable news
0
All posts from Actionable news
Actionable news in TKAI: TOKAI PHARMACEUTICALS Inc,

Tokai Pharma terminates late-stage study of lead product candidate in prostate cancer; shares plummet 70% premarket

Thinly traded micro cap Tokai Pharmaceuticals (NASDAQ:TKAI) craters 70% premarket on higher-than-normal volume in response to its announcement that it will stop its Phase 3 clinical trial, ARMOR3-SV, assessing lead product candidate galeterone compared to enzalutamide (XTANDI) in treatment-naive men with metastatic castration-resistant prostate cancer...


More